The
global pacemaker market size is anticipated to reach USD
5.8 billion by 2027, expanding at a CAGR of 2.9%, as per the new report by
Grand View Research, Inc. The increasing prevalence of cardiovascular diseases
is a key growth driver for the market. As per the CDC, in 2017, CVDs accounted
for about 800,000 deaths in the U.S alone. Moreover, coronary heart disease
accounts for the highest number of deaths, followed by stroke and heart
failure.
As
per the British Heart Foundation Centre in 2018, nearly 7.4 million individuals
are living with circulatory and heart diseases in the UK. More than 43,000
individual under 75 years of age dies due to cardiac diseases every year in the
UK. To curb the rising prevalence of CVDs is government bodies and key market
players are channelizing revenues to offer a potential treatment. This is
anticipated by the influx of advanced products in this market space.
As
per the CDC, 2020, more than 15.0% of U.S. adults are physically inactive that
shows the prevalence of adult physical inactivity. Technological developments
are quickly renovating the market. Key players are focusing on expanding their
current portfolio such as in January 2020, BIOTRONIK launched an injectable
cardiac monitor, BIOMONITOR III in Japan. It is intended to measure irregular
heart rhythms with increased clarity. The injectable cardiac monitor also
documents the unexplained syncope. Moreover, in January 2019, Medtronic
launched MyCareLink Heart (TM)-a mobile app for communicating directly with
patients via smartphones.
Full Research Report On Pacemaker Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/pacemaker-market
Pacemaker Market
Report Highlights
- MRI
compatible pacemakers is the fastest-growing segment from 2020 to 2027
owing toa higher patient preference rate as 75% of the patients with
pacemakers are likely to get MRI during their lifetimes
- Atrial
Fibrillation held the largest market share in 2019 owing to the
heightened prevalence of growing with age. As per the National Center for
Biotechnology Information, 2020, nearly 6 to 12 million people globally
are expected to suffer from atrial fibrillation in the US alone by 2050
- The
biventricular chamber product segment is expected to be the
fastest-growing segment from 2020 to 2027. The device is also is known as
Cardiac Resynchronization Therapy (CRT) device. An increase in the
prevalence of heart failure is one of the major factors driving the growth
of the segment
- Key companies
are adopting new strategies to attain a competitive edge. Product
development, collaborations, partnerships, mergers and acquisitions, and
regional expansion are few of them.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/pacemaker-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment